Skip to main content
Premium Trial:

Request an Annual Quote

CombiMatrix, Clarient Partner on CLL Test

NEW YORK (GenomeWeb News) – CombiMatrix announced this morning that it will collaborate with Clarient in marketing and selling CombiMatrix’s HemeScan, a prognostic and diagnostic monitoring tool, for chronic lymphocytic leukemia.
The test was developed by CombiMatrix in collaboration with researchers at the MD Anderson Cancer Center in Houston, the University of Texas Health Sciences Center in San Antonio, and the Netherlands Cancer Institute in Amsterdam.
Cancer diagnostics services lab Clarient will market the tests to pathologists, oncologists, and patients, under the agreement.
According to CombiMatrx, the test provides prognostic marker precision with simultaneous diagnostic monitoring of the entire genome in CLL. The firm said that the test also has been validated for acute lymphoblastic leukemia and myelodysplastic syndrome, and it is currently being tested for multiple myeloma.
CombiMatrix said there are more than 10,000 new cases of CLL annually in the US and over 150,000 patients living with the disease.

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.